Ocular Therapeutix, Inc. (NASDAQ:OCUL) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing share count, pipeline status, and financial statement structure for the third quarter of its fiscal year.
Key Highlights
- Shares outstanding: As of November 6, 2026, there were 220,022,840 shares of Common Stock, $0.0001 par value per share, outstanding.
- Filer classification: The company is designated a large accelerated filer, not a smaller reporting company or emerging growth company.
- Lead pipeline candidate: AXPAXLI is the subject of multiple active registrational trials, including the Phase 3 SOL-1 trial for wet age-related macular degeneration and the Phase 3 HELIOS-3 trial for non-proliferative diabetic retinopathy.
- Commercialized product: DEXTENZA is the company's marketed product, with ongoing commercialization efforts described in the filing.
- Additional candidate: OTX-TIC for open-angle glaucoma or ocular hypertension is listed as a product candidate, with the company disclosing it is determining next steps.
- International collaboration: The company holds a license agreement and collaboration with AffaMed Therapeutics Limited covering development and commercialization of DEXTENZA and OTX-TIC across mainland China, Taiwan, Hong Kong, Macau, South Korea, and countries of the Association of Southeast Asian Nations.
Pipeline Activity and Commercial Operations at Ocular Therapeutix
According to the filing, Ocular Therapeutix is a Delaware-incorporated biopharmaceutical company headquartered at 14 Crosby Drive, 3rd Floor, Bedford, MA 01730. The company develops ophthalmic therapies based on its proprietary bioresorbable hydrogel-based formulation technology, which the filing refers to as ELUTYX. DEXTENZA is the company's currently marketed product, and the filing describes active commercialization, marketing, and manufacturing efforts surrounding it.
The filing identifies AXPAXLI as the central pipeline candidate. Four separate clinical programs are described: the SOL-1 Phase 3 trial for wet AMD, the SOL-R repeat-dosing study for wet AMD, the SOL-X long-term extension study for wet AMD, and the HELIOS-3 Phase 3 trial for non-proliferative diabetic retinopathy. The company also disclosed plans to submit a new drug application for AXPAXLI based on SOL-1 Week 52 data, interim safety data from the SOL-R trial, and what the filing calls "confirmatory evidence." These are the company's own stated plans and are subject to the cautionary language contained in the filing's forward-looking statements section.
The filing notes that forward-looking statements involve "substantial risks and uncertainties" and that actual results "could differ materially from the plans, intentions and expectations disclosed." The company expressly disclaimed any obligation to update forward-looking statements except as required by applicable law. The Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 5, 2026, is referenced as a source of additional risk factor disclosures.
What Was Disclosed
The Form 10-Q for the quarter ended September 30, 2026 covers Ocular Therapeutix's financial statements, management discussion, and pipeline disclosures. The filing confirms 220,022,840 shares outstanding as of November 6, 2026, identifies the company as a large accelerated filer, and outlines active registrational trials for AXPAXLI alongside continued commercialization of DEXTENZA.



Please wait processing your request...